Expert Answers to HCP Questions on Androgen Deprivation Therapy for Prostate Cancer

In this episode, Daniel W. Lin, MD; Alicia K. Morgans, MD, MPH; and David F. Penson, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in androgen deprivation therapy, with questions including:

• How to select between GnRH agonists and antagonists for initial androgen deprivation therapy?
• How should androgen receptor inhibitors be incorporated into treatment paradigms for nonmetastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer?
• How should patients with prostate cancer and bone density issues be managed?
• How should nonmetastatic and metastatic prostate cancer be classified in light of novel imaging modalities, and how does this affect treatment?

Presenters:

Daniel W. Lin, MD
Professor and Chief of Urologic Oncology
Department of Urology
University of Washington
Seattle, Washington

Alicia K. Morgans, MD, MPH
Genitourinary Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

David F. Penson, MD
Professor and Chair
Department of Urology
Vanderbilt University School of Medicine
Nashville, Tennessee

 Content based on an online CME program supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Myovant Sciences Ltd, and Pfizer, Inc.  

Link to full program:
https://bit.ly/3iFCis5    

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.